Products for Research Use Only

AMZ30

CAT: 0804-HY-12833-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12833-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AMZ30 is selective protein phosphatase methylesterase-1 (PME-1) inhibitor with IC50s of 600 nM and 3.5 µM in human cell lysates and in HEK 293T cells, respectively. AMZ30 shows >100-fold selectivity relative to other serine hydrolases. AMZ30 reduces the demethylated form of PP2A in living cells. AMZ30 attenuates muscle cell differentiation. AMZ30 increases the resistance of U87MG and U251MG glioblastoma cells to t-BHP-induced oxidative stress. AMZ30can be used for the study of glioblastoma[1][2][3].
CAS Number
1313613-09-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; ERK; Phosphatase
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/AMZ30.html
Purity
99.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(C1=CC([N+]([O-])=O)=CC=C1)(N2C(/C=C(S(=O)(C3=CC=C(F)C=C3)=O)\C#N)=CC=C2)=O
Molecular Formula
C19H12FN3O6S2
Molecular Weight
461.44
Precautions
H302, H315, H319, H335
References & Citations
[1]Labuzan SA, et al. Inhibition of protein phosphatase methylesterase 1 dysregulates MAP kinase signaling and attenuates muscle cell differentiation. Gene. 2020 May 20;739:144515.|[2]Guffens L, et al. PME-1 sensitizes glioblastoma cells to oxidative stress-induced cell death by attenuating PP2A-B55α-mediated inactivation of MAPKAPK2-RIPK1 signaling. Cell Death Discov. 2023 Jul 27;9 (1) :265.|[3]Bachovchin DA, et al. Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem. 2011 Jul 28;54 (14) :5229-36.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported